What You Should Know:
– Eli Lilly’s Kisunla™ (donanemab-azbt) has been approved by the FDA as a treatment for adults in the early stages of Alzheimer’s disease (AD), including those with mild cognitive impairment (MCI)…
Continue Reading
What You Should Know:
– ALZpath, a leader in Alzheimer’s disease diagnostics, announced a licensing agreement with Roche for their innovative pTau217 antibody. This paves the way for a blood test to diagnose Alzheimer’s disease…
Continue Reading
A mobile application used to assess sports-related head and brain injuries is now being tested for detecting and monitoring neurological disorders. BrainEye’s mobile test is now being studied in clinical trials at The Alfred Hospital…
Continue Reading
What You Should Know:
– GE HealthCare announced the unveiling of SIGNA MAGNUS, a revolutionary head-only magnetic resonance imaging (MRI) scanner.
– This FDA 510(k) pending technology holds immense promise for unlocking new frontiers in neuroscience…
Continue Reading
Remote monitoring of cognition holds the promise to facilitate case-finding in clinical care and the individual detection of cognitive impairment in clinical and research settings. In the context of Alzheimer’s disease, this is particularly…
Continue Reading
Brain fog is a common symptom of menopause, though it can be worrying for some women, particularly if their family has a history of dementia or Alzheimer’s. To help women determine if they are…
Continue Reading
What You Should Know:
– Neurocode USA, Inc., a provider of neurological testing, has announced the launch of ALZpath Dx, a novel blood test for Alzheimer’s disease (AD) in the United States.
– The availability of…
Continue Reading
Drug repurposing represents an attractive alternative to the costly and time-consuming process of new drug development, particularly for serious, widespread conditions with limited effective treatments, such as Alzheimer’s disease (AD). Emerging generative artificial intelligence…
Continue Reading
By Shania Kennedy
February 02, 2024 – Researchers from the University of Texas at Arlington (UTA) have developed a model to predict how a patient’s Alzheimer’s will progress over time, according to a study published recently…
Continue Reading
Augmented reality (AR) apps, in which the virtual and real world are combined, can recreate instrumental activities of daily living (IADL) and are therefore promising to measure cognition needed for IADL in early Alzheimer’s…
Continue Reading
